Karim R Saab1,2, Meghan J Mooradian3, Daniel Y Wang4, Jeewon Chon4, Cathy Y Xia5, Angelica Bialczak1, Kelly T Abbate1, Alexander M Menzies5,6, Douglas B Johnson4, Ryan J Sullivan3, Alexander N Shoushtari1,2. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Weill Cornell Medical College, New York, New York. 3. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 4. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia. 6. The University of Sydney, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: Combined BRAF and MEK inhibition (BRAF-MEK) is a standard therapy for patients with BRAF V600-mutant melanoma, but to the authors' knowledge, the tolerance, adverse event (AE) profile, and efficacy have not been well defined in the post-programmed cell death protein 1 (PD-1) setting. METHODS: Patients with BRAF V600-mutant melanoma who received combined BRAF-MEK after prior PD-1-based therapy were assembled from 4 tertiary care centers in the United States and Australia. Dose modification was defined as a treatment break, dose reduction, or intermittent dosing. Rates of hospitalization and discontinuation due to AEs were collected, and overall survival (OS) was calculated using Kaplan-Meier methods from the time of the initiation of BRAF-MEK therapy. RESULTS: A total of 78 patients were identified as having received a BRAF-MEK regimen at a median of 34 days after the last dose of PD-1-based therapy. The majority of patients (86%) received the combination of dabrafenib and trametinib. Approximately 80% of patients had American Joint Committee on Cancer M1c or M1d disease. Sixty-five regimens (83%) had ≥1 dose modification. The median time to the first dose modification was 14 days; 86% occurred within 90 days and 71% involved pyrexia. Dose modifications were more common in patients receiving BRAF-MEK <90 days after the last dose of PD-1 and who were not receiving steroids. Of the dose modifications, 25 (31%) led to an AE-related hospitalization. Among 55 BRAF-naive patients, the median time receiving BRAF-MEK therapy was 5.8 months and the median OS was 15.6 months. CONCLUSIONS: The majority of patients receiving BRAF-MEK inhibition after PD-1 therapy require dose interruptions, and a significant minority require hospitalization for AEs. In this higher risk population, the median time receiving therapy and OS may be inferior to those presented in published phase 3 trials.
BACKGROUND: Combined BRAF and MEK inhibition (BRAF-MEK) is a standard therapy for patients with BRAF V600-mutant melanoma, but to the authors' knowledge, the tolerance, adverse event (AE) profile, and efficacy have not been well defined in the post-programmed cell death protein 1 (PD-1) setting. METHODS:Patients with BRAF V600-mutant melanoma who received combined BRAF-MEK after prior PD-1-based therapy were assembled from 4 tertiary care centers in the United States and Australia. Dose modification was defined as a treatment break, dose reduction, or intermittent dosing. Rates of hospitalization and discontinuation due to AEs were collected, and overall survival (OS) was calculated using Kaplan-Meier methods from the time of the initiation of BRAF-MEK therapy. RESULTS: A total of 78 patients were identified as having received a BRAF-MEK regimen at a median of 34 days after the last dose of PD-1-based therapy. The majority of patients (86%) received the combination of dabrafenib and trametinib. Approximately 80% of patients had American Joint Committee on Cancer M1c or M1d disease. Sixty-five regimens (83%) had ≥1 dose modification. The median time to the first dose modification was 14 days; 86% occurred within 90 days and 71% involved pyrexia. Dose modifications were more common in patients receiving BRAF-MEK <90 days after the last dose of PD-1 and who were not receiving steroids. Of the dose modifications, 25 (31%) led to an AE-related hospitalization. Among 55 BRAF-naive patients, the median time receiving BRAF-MEK therapy was 5.8 months and the median OS was 15.6 months. CONCLUSIONS: The majority of patients receiving BRAF-MEK inhibition after PD-1 therapy require dose interruptions, and a significant minority require hospitalization for AEs. In this higher risk population, the median time receiving therapy and OS may be inferior to those presented in published phase 3 trials.
Authors: Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: B Dréno; A Ribas; J Larkin; P A Ascierto; A Hauschild; L Thomas; J-J Grob; D O Koralek; I Rooney; J J Hsu; E F McKenna; G A McArthur Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976
Authors: Paolo A Ascierto; Grant A McArthur; Brigitte Dréno; Victoria Atkinson; Gabrielle Liszkay; Anna Maria Di Giacomo; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Caroline Dutriaux; Claus Garbe; Yibing Yan; Matthew Wongchenko; Ilsung Chang; Jessie J Hsu; Daniel O Koralek; Isabelle Rooney; Antoni Ribas; James Larkin Journal: Lancet Oncol Date: 2016-07-30 Impact factor: 41.316
Authors: Douglas B Johnson; Eirini Pectasides; Emily Feld; Fei Ye; Shilin Zhao; Romany Johnpulle; Ryan Merritt; David F McDermott; Igor Puzanov; Donald Lawrence; Jeffrey A Sosman; Elizabeth Buchbinder; Ryan J Sullivan Journal: J Immunother Date: 2017-01 Impact factor: 4.456
Authors: Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long Journal: Lancet Oncol Date: 2017-06-04 Impact factor: 41.316
Authors: Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo Journal: Cell Date: 2016-03-17 Impact factor: 41.582
Authors: Clara I Lee; Alexander M Menzies; Lauren E Haydu; Mary Azer; Arthur Clements; Richard F Kefford; Georgina V Long Journal: Melanoma Res Date: 2014-10 Impact factor: 3.599
Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245
Authors: Paolo A Ascierto; Sanjiv S Agarwala; Alexander Eggermont; Jeffrey E Gershenwald; Jean-Jacques Grob; Omid Hamid; Olivier Michielin; Michael Postow; Igor Puzanov; Hassane M Zarour; Corrado Caracò; Alessandro Testori Journal: J Transl Med Date: 2020-04-16 Impact factor: 5.531